Printer Friendly

IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS

 NORCROSS, Ga., July 19 /PRNewswire/ -- Immucor, Inc. (NASDAQ-NMS: BLUD), maker of blood bank reagent systems and related products, announced today net income for the year ended May 31, totaled $1,832,380 compared to $3,043,496 a year ago.
 Earnings per share for the year were $.25 vs. $.35 per share last year. For the three month period ended May 31, net income was essentially break even, compared to $635,696 a year ago, with zero earnings per share, vs. $.08 per share last year.
 Net sales for the year ended May 31, increased 10 percent to $30,070,367 vs. $27,262,602 a year ago. Net sales for the fourth quarter were $7,594,042, compared to $7,343,581 last year.
 Commenting on year-end results, Edward L. Gallup, president of Immucor, Inc., said: "Research and development spending of $1,245,200 for our previously announced automated blood bank instrument product, combined with declining operating margins in Europe, particularly in Germany, and foreign currency transaction losses on purchases of inventory, primarily in Italy, caused a substantial drop in earnings over last year. As a result, we have begun cost saving measures to reduce operating expenses while the instrument project moves forward. These include: a hiring freeze, an immediate salary freeze at current levels and an overall review of staffing needs."
 Founded in 1982, Immucor manufactures and sells a complete line of reagents and systems used primarily by hospitals and blood banks in a number of tests performed to detect and identify certain properties of the cell and serum components of human blood prior to blood transfusion.
 IMMUCOR, INC.
 Statements of Income
 (Unaudited)
 Three Months Ended Twelve Months Ended
 5/31/93 5/31/92 5/31/93 5/31/92
 Net sales $7,594,042 $7,343,581 $30,070,367 $27,262,602
 Cost of sales 3,228,696 3,266,920 11,673,962 11,353,638
 Gross profit 4,365,346 4,076,661 18,396,405 15,908,964
 Research and development:
 Contract 450,371 --- 1,245,199 ---
 General 119,880 101,992 466,240 481,220
 Selling, general and
 administrative 3,524,461 3,035,087 13,302,009 10,990,739
 Total operating
 expenses 4,094,712 3,137,079 15,013,448 11,471,959
 Income from
 operations 270,634 939,582 3,382,957 4,437,005
 Other income 115,727 170,387 555,863 802,736
 Interest expense (180,478) (194,368) (773,309) (631,341)
 Other expense (7,423) (17,978) (167,783) (39,504)
 Total other (72,174) (41,959) (385,229) 131,891
 Income before
 income taxes 198,460 897,623 2,997,728 4,568,896
 Provision for
 income taxes 186,495 261,927 1,165,348 1,525,400
 Net income $ 11,965 $635,696 $1,832,380 $3,043,496
 Net income per common
 and common equivalent
 share $0.00 $0.08 $0.25 $0.35
 Balance sheet available upon request.
 -0- 7/19/93
 /CONTACT: Richard J. Still, senior vice president-Finance of Immucor, 404-441-2051/
 (BLUD)


CO: Immucor, Inc. ST: Georgia IN: MTC SU: ERN

BR -- AT001 -- 2865 07/19/93 08:12 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Jul 19, 1993
Words:532
Previous Article:WESTINGHOUSE COMMUNICATIONS OFFERS BUSINESS CUSTOMERS 800 SERVICES
Next Article:OWENS & MINOR, INC., ANNOUNCES IMPROVED 1993 SECOND QUARTER AND SIX-MONTH EARNINGS
Topics:


Related Articles
IMMUCOR SEES FLAT EARNINGS FOR FISCAL YEAR
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR REPORTS FIRST QUARTER RESULTS
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR REPORTS YEAR-END AND FOURTH QUARTER RESULTS
IMMUCOR REPORTS SECOND QUARTER RESULTS
IMMUCOR REPORTS THIRD QUARTER RESULTS
IMMUCOR ANTICIPATES LOWER EARNINGS
IMMUCOR REPORTS YEAR END RESULTS
Immucor Reports Third Quarter Results

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters